# A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)

> **NCT00960063** · PHASE1 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 4 (actual)

## Conditions studied

- Neoplasms
- Solid Tumors
- Bone Cancer
- Kidney Tumor
- Neuroblastoma

## Interventions

- **DRUG:** Temozolomide
- **DRUG:** Vincristine
- **DRUG:** Ifosfamide
- **DRUG:** Irinotecan
- **BIOLOGICAL:** Robatumumab
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT00960063
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-11-11
- **Primary completion:** 2010-12-22
- **Final completion:** 2010-12-22
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Study was terminated for business reasons.
- **Last updated:** 2018-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00960063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00960063, "A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00960063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*